Albuvirtide LA is under clinical development by Frontier Biotechnologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Albuvirtide LA’s likelihood of approval (LoA) and phase transition for Human Immunodeficiency Virus (HIV) Infections (AIDS) took place on 16 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Albuvirtide LA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Albuvirtide LA overview

Albuvirtide (Aikening) is a 3-maleimimidopropionic acid (MPA)-modified peptide, acts as an anti-HIV agent. It is formulated as long-acting release injectable powder for solution for intravenous route of administration. Aikening is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with lopinavir or ritonavir (LPV/r) suppressed HIV replication in adults who failed the standard first-line antiretroviral drug.

FB-006M (albuvirtide) is under development for the treatment of human immunodeficiency virus (HIV) infection in combination with 3BNC-117 in the U.S.

Frontier Biotechnologies overview

Frontier Biotechnologies (Frontier) is a clinical-stage pharmaceutical company that offers drug discovery and development business models, and clinical research services. The company’s pipeline products comprise FB1002, novel broad-spectrum HIV neutralizing antibody; FB3001, new transdermal patch for the treatment of musculoskeletal pain; and FB2001, a novel coronavirus (SARS-CoV-2) protease inhibitor. It also offers Aikening, a HIV fusion inhibitor to treat human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). Frontier also carries out research and development activities in the field of HIV long-acting treatment and immunotherapy in China and the US. The company collaborates with manufacturers and commercial distributors to bring innovative drugs for unmet clinical needs. Frontier is headquartered in Nanjing, Jiangsu, China.

Quick View Albuvirtide LA LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Albuvirtide LA
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.